ACHONDROPLASIA
Clinical trials for ACHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new ACHONDROPLASIA trials appear
Sign up with your email to follow new studies for ACHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to help kids with dwarfism grow taller
Disease control Recruiting nowThis study is testing an oral drug called TYRA-300 in children aged 3 to 10 with achondroplasia, the most common form of dwarfism. The main goals are to see if the drug is safe and to find the right dose that might help children grow faster. Researchers will measure changes in th…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Tracking Kids' growth to understand achondroplasia
Disease control Recruiting nowThis study aims to collect detailed information about growth, health complications, and quality of life in children with achondroplasia. Researchers will follow 260 children aged 2.5 to 11 years for 6 months to 2 years to better understand the natural course of this condition. Th…
Matched conditions: ACHONDROPLASIA
Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for little ones: daily pill aims to boost growth in common dwarfism
Disease control Recruiting nowThis study is testing whether a daily oral medicine called infigratinib is safe and can help improve growth and development in infants and toddlers under 3 years old with achondroplasia, the most common form of dwarfism. Researchers will compare the medicine to a placebo (a pill …
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for babies with dwarfism: weekly shot aims to boost growth
Disease control Recruiting nowThis study is testing a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, a genetic condition that causes short stature. The main goals are to see if the treatment is safe and if it helps children grow taller over 52 weeks. Infants will be ran…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New weekly shot aims to boost growth in teens with dwarfism
Disease control Recruiting nowThis trial is testing whether a new weekly injection called navepegritide can safely increase the annual growth rate in adolescents (ages 12-18) with achondroplasia, a genetic condition that causes dwarfism. About 24 participants will receive either the active drug or a placebo (…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Wearable tech tracks daily movement in rare growth condition
Knowledge-focused Recruiting nowThis study aims to test how well a wearable sensor device, called Syde®, can reliably measure limb movements in people with achondroplasia or hypochondroplasia. About 40 participants aged 3 and older will wear the device at home over a year to collect movement data. The goal is t…
Matched conditions: ACHONDROPLASIA
Sponsor: SYSNAV • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Tracking little lives: major study follows children with dwarfism for 5+ years
Knowledge-focused Recruiting nowThis study aims to understand how children with achondroplasia grow and develop over time, particularly those taking the medication VOXZOGO™. Researchers will follow 170 participants (mostly children under 14) for at least 5 years by collecting their medical records and asking fa…
Matched conditions: ACHONDROPLASIA
Sponsor: BioMarin Pharmaceutical • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC